I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
天境生物巨震：管理層變動、收購傳聞、退市風險

Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low.
抗癌藥研發公司天境生物最近頻繁出現在一系列影響市場的頭條新聞中，儘管股票仍接近歷史最低點。

詠竹坊

更新於2022年5月9日 14:05 詠竹坊

There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab (IMAB.US), whose stock is getting pulled every which way as a result.

作者劉小燕本文僅代表作者個人觀點

您已閱讀2%（183字），剩餘98%（8291字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。

詠竹坊

詠竹坊（官網鏈接）提供在香港和美國上市的中國企業相關新聞，重點關注中小企業和籌備上市的公司。

Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
天境生物巨震：管理層變動、收購傳聞、退市風險

詠竹坊

製藥業

相關話題

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat天境生物巨震：管理層變動、收購傳聞、退市風險

詠竹坊

製藥業

相關話題

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
天境生物巨震：管理層變動、收購傳聞、退市風險